Cure My Disease

Don't miss your cure!

 Log in / Sign up

Tiny particles, big hope: new combo tackles tough cancers

NCT ID NCT04789486

Recruiting now Disease control Sponsor: Dana-Farber Cancer Institute Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether injecting gadolinium-based nanoparticles (AGuIX) before precise MR-guided radiation can improve tumor control for people with centrally located lung tumors or locally advanced pancreatic cancer. About 100 participants will receive the nanoparticle injection plus radiation, and researchers will monitor safety and how well the tumors shrink or stop growing. The goal is to find the best dose and see if this combination works better than radiation alone.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
AGuIX gadolinium-based nanoparticles
What this could lead to
If successful, this could offer a more effective way to control central lung tumors and locally advanced pancreatic cancer with fewer side effects.
What could go wrong
This is an early phase 1-2 trial with only 100 participants, so results may not apply broadly. Nanoparticles could cause unexpected toxicity or fail to improve outcomes over standard radiation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm non-small cell lung carcinoma pancreatic adenocarcinoma pancreatic ductal adenocarcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED PANCREATIC ADENOCARCINOMA DUCTAL ADENOCARCINOMA OF THE PANCREAS NON-SMALL CELL LUNG CANCER UNRESECTABLE PANCREATIC CANCER

Contacts and locations

Locations

  • Brigham and Women's Hospital

    RECRUITING

    Boston, Massachusetts, 02115, United States

  • Dana Farber Cancer Institute

    RECRUITING

    Boston, Massachusetts, 02115, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.